Literature DB >> 19342634

The amino acid sequences flanking an antigenic determinant can strongly affect MHC class I cross-presentation without altering direct presentation.

Xueying Ma1, Amparo Serna, Ren-Huan Xu, Luis J Sigal.   

Abstract

Direct presentation (DP) and cross presentation (CP) on MHC I by professional APCs are defined by the internal or external source of the Ag, respectively. Although some Ags are substrates for both DP and CP, others are only substrates for DP. The reasons for this difference remain largely unknown. In this study, we studied in tissue culture and also in vivo, the effects of altering the length and sequence of the amino acid chains flanking an MHC class I restricted determinant (the chicken OVA OVA(258-265), SIINFEKL) that is normally a good substrate for both DP and CP. We demonstrate that CP but not DP strictly requires flanking N and C-terminal extensions of minimal length. Furthermore, we show that removal but not replacement of just one amino acid 22 residues downstream from the determinant is sufficient to strongly affect CP without affecting either protein stability or DP. Thus, our work shows that the flanking residues of an antigenic determinant can differentially affect CP and DP, and that features of the Ag other than half-life can have a major impact in CP. Our studies may have implications for understanding CP in viral infections and possibly for the design of new vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342634      PMCID: PMC2756161          DOI: 10.4049/jimmunol.0803806

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides.

Authors:  A X Mo; S F van Lelyveld; A Craiu; K L Rock
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

2.  Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization.

Authors:  J H Cho; J W Youn; Y C Sung
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

3.  Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells.

Authors:  Amparo Serna; Maria C Ramirez; Anna Soukhanova; Luis J Sigal
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

Review 4.  Cross priming or direct priming: is that really the question?

Authors:  Christopher C Norbury; Luis J Sigal
Journal:  Curr Opin Immunol       Date:  2003-02       Impact factor: 7.486

Review 5.  On cross-priming of MHC class I-specific CTL: rule or exception?

Authors:  Rolf M Zinkernagel
Journal:  Eur J Immunol       Date:  2002-09       Impact factor: 5.532

6.  Antigen bias in T cell cross-priming.

Authors:  Monika C Wolkers; Nathalie Brouwenstijn; Arnold H Bakker; Mireille Toebes; Ton N M Schumacher
Journal:  Science       Date:  2004-05-28       Impact factor: 47.728

7.  Macrophages and dendritic cells use the cytosolic pathway to rapidly cross-present antigen from live, vaccinia-infected cells.

Authors:  Maria Carmen Ramirez; Luis J Sigal
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

Review 8.  Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?

Authors:  Cornelis J M Melief
Journal:  Eur J Immunol       Date:  2003-10       Impact factor: 5.532

9.  A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection.

Authors:  Michael Quigley; Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  Blood       Date:  2008-10-23       Impact factor: 22.113

10.  Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation.

Authors:  L J Sigal; K L Rock
Journal:  J Exp Med       Date:  2000-10-16       Impact factor: 14.307

View more
  7 in total

1.  High-frequency vaccine-induced CD8⁺ T cells specific for an epitope naturally processed during infection with Mycobacterium tuberculosis do not confer protection.

Authors:  Thomas Lindenstrøm; Claus Aagaard; Dennis Christensen; Else M Agger; Peter Andersen
Journal:  Eur J Immunol       Date:  2014-03-27       Impact factor: 5.532

2.  Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation.

Authors:  Angela M Tatum; Alan M Watson; Todd D Schell
Journal:  J Immunol       Date:  2010-07-26       Impact factor: 5.422

3.  Direct presentation is sufficient for an efficient anti-viral CD8+ T cell response.

Authors:  Ren-Huan Xu; Sanda Remakus; Xueying Ma; Felicia Roscoe; Luis J Sigal
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

4.  Prolonged antigen presentation following an acute virus infection requires direct and then cross-presentation.

Authors:  Erica L Heipertz; Michael L Davies; Eugene Lin; Christopher C Norbury
Journal:  J Immunol       Date:  2014-09-15       Impact factor: 5.422

5.  Location of the CD8 T cell epitope within the antigenic precursor determines immunogenicity and protection against the Toxoplasma gondii parasite.

Authors:  Virginie Feliu; Virginie Vasseur; Harshita S Grover; H Hamlet Chu; Mark J Brown; Jeremy Wang; Jon P Boyle; Ellen A Robey; Nilabh Shastri; Nicolas Blanchard
Journal:  PLoS Pathog       Date:  2013-06-20       Impact factor: 6.823

Review 6.  Cross-Presentation of Cell-Associated Antigens by MHC Class I in Dendritic Cell Subsets.

Authors:  Enric Gutiérrez-Martínez; Remi Planès; Giorgio Anselmi; Matthew Reynolds; Shinelle Menezes; Aimé Cézaire Adiko; Loredana Saveanu; Pierre Guermonprez
Journal:  Front Immunol       Date:  2015-07-17       Impact factor: 7.561

7.  Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.

Authors:  Cristian Capasso; Mari Hirvinen; Mariangela Garofalo; Dmitrii Romaniuk; Lukasz Kuryk; Teea Sarvela; Andrea Vitale; Maxim Antopolsky; Aniket Magarkar; Tapani Viitala; Teemu Suutari; Alex Bunker; Marjo Yliperttula; Arto Urtti; Vincenzo Cerullo
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.